지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 1 - 11 (11page)
이용수
초록· 키워드
오류제보하기
Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of endstage liver disease and cardiometabolic disease, resulting in liver-related and non-liver–related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.
목차
등록된 정보가 없습니다.
참고문헌 (82)
참고문헌 신청
강윤구 / 2018 / Estimated Prevalence of Adolescents with Nonalcoholic Fatty Liver Disease in Korea / Journal of Korean Medical Science 33(14):29~38
Chalasani N / 2018 / The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American Association for the Study of Liver Diseases / Hepatology 67:328~357
Sanyal AJ / 2011 / Endpoints and clinical trial design for nonalcoholic steatohepatitis / Hepatology 54:344~353
Konerman MA / 2018 / Pharmacotherapy for NASH : current and emerging / J Hepatol 68:362~375
Kleiner DE / 2005 / Design and validation of a histological scoring system for nonalcoholic fatty liver disease / Hepatology 41:1313~1321
Chalasani N / 2018 / The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American Association for the Study of Liver Diseases / Hepatology 67:328~357
Sanyal AJ / 2011 / Endpoints and clinical trial design for nonalcoholic steatohepatitis / Hepatology 54:344~353
Konerman MA / 2018 / Pharmacotherapy for NASH : current and emerging / J Hepatol 68:362~375
Kleiner DE / 2005 / Design and validation of a histological scoring system for nonalcoholic fatty liver disease / Hepatology 41:1313~1321
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Clinical and Molecular Hepatology
2023 .02
-
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2020 .01
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
Journal of Yeungnam Medical Science
2019 .01
-
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
영남의대학술지
2019 .01
-
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Endocrinology and Metabolism
2022 .02
-
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Clinical and Molecular Hepatology
2023 .02
-
The Immune Landscape in Nonalcoholic Steatohepatitis
Immune Network
2016 .06
-
Nonalcoholic fatty liver disease and non-liver comorbidities
Clinical and Molecular Hepatology
2023 .02
-
Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients
전남의대학술지
2024 .01
-
Risk factors in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease
Journal of Obesity & Metabolic Syndrome
2022 .03
-
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Diabetes and Metabolism Journal
2019 .01
-
비알코올성 지방간 질환의 진단적 평가
대한내과학회지
2020 .10
-
Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
Gut and Liver
2022 .03
-
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Endocrinology and Metabolism
2020 .01
-
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
Diabetes and Metabolism Journal
2019 .01
-
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Clinical and Molecular Hepatology
2023 .02
-
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Clinical and Molecular Hepatology
2023 .04
-
Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index
Gut and Liver
2020 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0